{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-300412","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.995481+00:00","generated_at":"2026-06-07T09:08:37.158630+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bioventus appoints Robert Claypoole as President and CEO effective Jan 10, 2024","bullets":["Claypoole appointed President and CEO effective Jan 10, 2024, succeeding interim CEO Anthony Bihl.","Compensation: $800k base, 100% bonus target, $750k sign-on cash, 375k RSUs and 850k options.","Claypoole previously EVP at Mölnlycke Health Care, leading $1.2B wound care; also held senior roles at Medtronic and Covidien.","Company reaffirms full year financial guidance previously announced on November 7, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-300412","json":"https://secwatch.observer/filing/0001193125-23-300412.json","markdown":"https://secwatch.observer/filing/0001193125-23-300412.md","text":"https://secwatch.observer/filing/0001193125-23-300412.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000119312523300412/0001193125-23-300412-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000119312523300412/d448507d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:08:37.158630+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1257f64dde","claim":"Robert E. Claypoole was appointed as President and Chief Executive Officer at Bioventus Inc..","evidence_excerpt":"Robert E. Claypoole has been appointed as the Company’s President and Chief Executive Officer, and as a Class III director of the Company, effective January 10, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000119312523300412/0001193125-23-300412-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c51ae0c048","claim":"Anthony P. Bihl III departed as Interim President and Chief Executive Officer at Bioventus Inc..","evidence_excerpt":"succeeding Anthony P. Bihl III, the Company’s current Interim President and Chief Executive Officer, in such roles.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000119312523300412/0001193125-23-300412-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"succeeded"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"fd02205ccc","claim":"Robert E. Claypoole was appointed as Class III Director at Bioventus Inc..","evidence_excerpt":"and as a Class III director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000119312523300412/0001193125-23-300412-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}